Development and implementation of a strategy for intensified screening for gambiense human African trypanosomiasis in Kongo Central province, DRC

PLoS Negl Trop Dis. 2020 Oct 15;14(10):e0008779. doi: 10.1371/journal.pntd.0008779. eCollection 2020 Oct.

Abstract

Background: The Democratic Republic of the Congo (DRC) accounts for the majority of the reported gambiense human African trypanosomiasis (HAT) cases. Kongo Central province in the DRC reports a relatively low, yet steady number of cases, and forms a transboundary focus with Angola and the Republic of Congo. This paper describes an intervention aimed at reducing the case burden in Kongo Central by improving passive case detection, complemented with reactive screening.

Methodology/principal findings: At the initiation of this programme in August 2015, 620 health facilities were identified and equipped with Rapid Diagnostic Tests (RDTs) for HAT screening. Of these, 603 (97%) reported use of RDTs, and 584 (94%) that continued to use RDTs to the last quarter of 2016 were used in the analysis going forward. Among all health facilities involved, 23 were equipped to confirm HAT by microscopy, and 4 of the latter were equipped to perform molecular testing with loop-mediated isothermal amplification (LAMP). Patients clinically suspected of HAT were tested with an RDT and those with a positive RDT result were referred to the nearest microscopy facility for confirmatory testing. If RDT positive patients were negative by microscopy, they were tested by LAMP, either on fresh blood or blood that was dried on filter paper and transported to a facility performing LAMP. This network of diagnostic facilities reduced the median distance for a patient to travel to a screening facility from 13.7km when the classical card agglutination test for trypanosomiasis (CATT) was used as a screening test in the past, to 3.4km. As a consequence, passive case detection was improved by between 30% and 130% compared to the period before. Furthermore, the proportion of HAT cases detected in early stage disease by passive screening increased from 27% to 64%. Reactive screening took place in 20 villages where cases were reported by passive screening, and in 45 villages in the neighbourhood of these villages. Reactive screening was responsible for detection of 40% of cases, of which, 90% were in first stage of the disease.

Conclusions: This programme has demonstrated that it is possible to deploy passive screening for HAT at sub-country or country levels in the DRC, and this is made more effective when supplemented with reactive screening. Results and achievements showed an increase in the number of HAT cases detected, the majority of them in early disease, demonstrating that this strategy enables better population coverage and early detection of cases, which is critical in removing the HAT reservoir and interrupting transmission, and could contribute to HAT elimination in regions where it is implemented.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Democratic Republic of the Congo / epidemiology
  • Diagnostic Tests, Routine
  • Humans
  • Mass Screening / methods*
  • Molecular Diagnostic Techniques
  • Nucleic Acid Amplification Techniques
  • Trypanosoma brucei gambiense / classification
  • Trypanosoma brucei gambiense / genetics
  • Trypanosoma brucei gambiense / isolation & purification*
  • Trypanosomiasis, African / diagnosis*
  • Trypanosomiasis, African / epidemiology
  • Trypanosomiasis, African / parasitology

Supplementary concepts

  • LAMP assay

Grants and funding

This work was funded through FIND by the Bill and Melinda Gates Foundation (www.gatesfoundation.org; grant OPP1033712), the Swiss Agency for Development and Cooperation (www.eda.admin.ch/sdc; grants No. 81019551 and 81050188) and the Department for International Development of the United Kingdom (www.gov.uk/government/organisations/department-for-international-development; grant No. 204074-101). Drugs for treating HAT cases were provided by WHO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this study.